Is Illumina (ILMN) Quietly Recasting Its Clinical Genomics Strategy With Eli Lilly’s R&D Chief on Board?
Illumina, Inc. recently expanded its Board from nine to ten members and appointed Daniel M. Skovronsky, M.D., Ph.D., an independent director and Eli Lilly’s Chief Scientific and Product Officer, effective June 16, 2026.
Bringing in a senior R&D leader with deep clinical and product experience may influence how Illumina prioritizes growth opportunities in clinical genomics and next-generation sequencing.
We’ll now examine how adding Eli Lilly’s R&D chief to Illumina’s board could shape the...
Generated by Pulse AI, Glideslope's proprietary engine for interpreting market sentiment and economic signals. For informational purposes only — not financial advice.